Skip to main content

Table 2 History of MDA, ITN use, LF complication, and ivermectin and albendazole distribution by FTS results, Togo

From: Monitoring migrant groups as a post-validation surveillance approach to contain the potential reemergence of lymphatic filariasis in Togo

 

Filariasis test strips (FTS)

P

 

Negative

Positive

Total

 

Mass drug administration for LF*, n (%)

   

 < 0.001**

 No

1155 (97.9)

25 (2.1)

1180

 

 Yes

170 (83.7)

33 (16.3)

203

 

 Unknown

8 (100.0)

0 (0.0)

8

 

ITN availability*, n (%)

   

0.354*

 No

505 (95.1)

26 (4.9)

531

 

 Yes

828 (96.3)

32 (3.7)

860

 

ITN use* during the night before the survey, n (%)

   

0.657**

 No

667 (95.6)

31 (4.4)

698

 

 Yes

651 (96.0)

27 (4.0)

678

 

 Unknown

15 (100.0)

0 (0.0)

15

 

History of LF complications, n (%)

   

 < 0.001*

 No

1297 (96.3)

50 (3.7)

1347

 

 Yes

36 (81.8)

8 (18.2)

44

 

Type of LF complication (n = 44), n (%)

   

0.006**

 Elephantiasis/ lymphedema

11 (100.0)

0 (0.0)

11

 

 Hydrocele/ elephantiasis/ lymphedema

2 (66.7)

1 (33.3)

3

 

 Hydrocele

19 (90.5)

2 (9.5)

21

 

 Unknown

4 (44.4)

5 (55.6)

9

 

Ever ivermectin (for onchocerciasis) and/or albendazole (for STH) distribution, n (%)

   

 < 0.001**

 No

1322 (100.0)

0 (0.0)

1322

 

 Yes

11 (15.9)

58 (84.1)

69

 

Type of migrant, n (%)

   

 < 0.001*

 Economic migrant

432 (98.9)

5 (1.1)

437

 

 Nomad Peuhl

325 (88.1)

44 (11.9)

369

 

 Refugee

576 (98.5)

9 (1.5)

585

 
  1. (*) Self-report based on recall; *Chi-square test; **Fisher test
  2. MDA mass drug administration, ITN insecticide-treated net, LF lymphatic filariasis, STH soil-transmitted helminths